Hutchison China MediTech has appointed Paul Rutherford Carter as its Senior Independent Non-Executive Director, and a member of several its committees.
He will be a member of Chi-Med’s Audit Committee, Remuneration Committee and Technical Committee of Chi-Med
Chi-Med has today been active in informing its shareholders about its endeavours. Earlier today the company announced launching two Phase two cancer drug studies in China.
In addition to all these news, it has also announced two resignations. Shigeru Endo tendered his resignation as Non-executive Director and Christopher Nash tendered his resignation as Senior Independent Non-executive Director and member of Audit Committee and Remuneration Committee. All the managerial changes are effective on February 1, 2017.